ERBB3 and neoplasm: Previous studies have suggested the use of HER3 chaperone kinases (such as HER2) as biomarkers, analysis of HER3 tumor levels using immunohistochemical assays, or using the expression of ligands that activate HER3 as biomarkers [29, 30].